| Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: systematic review and network meta-analysis E Fogarty, S Schmitz, N Tubridy, C Walsh, M Barry Multiple sclerosis and related disorders 9, 23-30, 2016 | 137 | 2016 |
| Incorporating data from various trial designs into a mixed treatment comparison model S Schmitz, R Adams, C Walsh Statistics in Medicine, 2013 | 118 | 2013 |
| A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian … S Schmitz, R Adams, CD Walsh, M Barry, O FitzGerald Annals of the rheumatic diseases 71 (2), 225-230, 2012 | 114 | 2012 |
| Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease M Ewers, S Schmitz, O Hansson, C Walsh, A Fitzpatrick, D Bennett, ... Neurobiology of aging 33 (8), 1599-1608, 2012 | 64 | 2012 |
| Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland L Tilson, M Jit, S Schmitz, C Walsh, P Garvey, P McKeown, M Barry Vaccine 29 (43), 7463-7473, 2011 | 42 | 2011 |
| The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma S Schmitz, Á Maguire, J Morris, K Ruggeri, E Haller, I Kuhn, J Leahy, ... BMC medical research methodology 18, 1-18, 2018 | 40 | 2018 |
| The use of continuous data versus binary data in MTC models: A case study in rheumatoid arthritis S Schmitz, R Adams, C Walsh BMC Medical Research Methodology 12 (1), 167, 2012 | 39 | 2012 |
| The Relative Efficacy of Boceprevir and Telaprevir in the Treatment of HCV Genotype 1 J Kieran, S Schmitz, A O’Leary, C Walsh, C Bergin, S Norris Clinical Infectious Diseases, 2012 | 38* | 2012 |
| Identifying and revealing the importance of decision-making criteria for health technology assessment: a retrospective analysis of reimbursement recommendations in Ireland S Schmitz, L McCullagh, R Adams, M Barry, C Walsh Pharmacoeconomics 34, 925-937, 2016 | 31 | 2016 |
| Safety of off-label erythropoiesis stimulating agents in critically ill patients: a meta-analysis B Mesgarpour, BH Heidinger, M Schwameis, C Kienbacher, C Walsh, ... Intensive care medicine 39, 1896-1908, 2013 | 30 | 2013 |
| Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy G Dranitsaris, S Schmitz, RJ Broom Journal of cancer research and clinical oncology 139, 1917-1926, 2013 | 27 | 2013 |
| The pharmacokinetic interaction between ivacaftor and ritonavir in healthy volunteers AM Liddy, G McLaughlin, S Schmitz, DM D'Arcy, MG Barry British journal of clinical pharmacology 83 (10), 2235-2241, 2017 | 17 | 2017 |
| Random main effects of treatment: a case study with a network meta‐analysis S Senn, S Schmitz, A Schritz, S Salah Biometrical Journal 61 (2), 379-390, 2019 | 4 | 2019 |
| Single Armed Observational Data To Closing The Gap In Otherwise Disconnected Evidence Networks S Schmitz, A Maguire, J Morris, C Walsh Value in Health 20 (9), A757, 2017 | | 2017 |
| PRM115 Modelling the Relationship Between Disease Severity and Utility in Multiple Sclerosis E Fogarty, C Walsh, S Grehan, S Schmitz, C McGuigan, N Tubridy, ... Value in Health 15 (7), A481, 2012 | | 2012 |
| PMS51 A Cost Utility Analysis of Anti-TNF Agents for the Treatment of Rheumatoid Arthritis RC Adams, C Walsh, S Schmitz, P Barton, M Barry Value in Health 14 (7), A311-A312, 2011 | | 2011 |
| MT2 The Use of Continuous Data versus Categorical Data in MTC: The Case of HAQ Multiplier in Rheumatoid Arthritis S Schmitz, RC Adams, C Walsh, M Barry Value in Health 14 (7), A237, 2011 | | 2011 |
| MT1 DOES MODEL CHOICE IN MIXED TREATMENT COMPARISONS AFFECT THE OUTCOME FOR DECISION-MAKERS? RC Adams, S Schmitz, O Fitzgerald, C Walsh, M Barry Value in Health 7 (13), A245, 2010 | | 2010 |
